Evaluation of the criteria for renewal of LHRH agonists in patients with prostate cancer: results of the ANAREN Study.

Introduction: Injectable extended-release formulations of luteinizing hormone-releasing hormone agonists (LHRHa) have simplified the treatment of prostate cancer with a satisfactory level of androgen castration. This study aims to determine the percentage of patients whose initial LHRHa prescription was renewed during follow-up, how many changed formulation and how their quality of life evolved. Methods: This is an observational, prospective, multicentre study of men with prostate cancer who were to receive treatment with LHRHa (triptorelin every 3 or 6 months, leuprorelin every 3 or 6 months, or goserelin every 3 months) for 24 months. The treatment used was recorded and quality of life was assessed (QLQ-PR25 questionnaire) at four follow-up visits. Results: A total of 497 men (median age 75 years) were evaluated. The median exposure to LHRHa was 24 months. The initial prescription was renewed in 95.7% at follow-up 1 and 75% at follow-up 4. The main reason for changing from a 6-month to a 3-month formulation was a preference for sequential treatment (according to the investigator) and to see the physician more frequently (according to the patient). The main reason for switching from the 3-month to 6-month formulation was simplification of treatment (according to the investigator) and for convenience (according to the patient). Findings in the QLQ-PR25 questionnaire revealed no changes in urinary or bowel symptoms, though an improvement in sexual activity was reported. Practically all investigators and patients were satisfied/very satisfied with the treatment. Conclusion: Changes in formulation were scarce and generally justified by convenience factors or personal preferences. Patients maintained a good health status, with a high rate of retention of LHRHa treatment. Clinical Trial Registration: Study number: A-ES-52014-224.A plain language summary is provided as supplementary material (available at: https://www.drugsincontext.com/wp-content/uploads/2024/05/dic.2024-2-2-Suppl.pdf).

Priapism Produced by Penile Metastasis from Colon Cancer.

INTRODUCTION AND OBJECTIVE: The penile metastasis is a rare clinical entity. The objective is to present the first documented case report of penile metastasis from right colon. CLINICAL CASE: A case of a 78-year-old man who was diagnosed with penile metastasis from right colon. The patient came to our consultation complaining of colic pain in the kidney and swelling of the penile which finally result in a malignant priapism. The diagnosis was histopathologic and was treated with chemotherapy and died few months later. CONCLUSION: Metastatic lesions in the penile are extremely rare; only 300 cases have been reported in the literature. It is a sign of bad prognosis. The mechanism of metastatic spread to the penis is not well established. Even there are several treatment options, is usually paliative.

[Relevance of clinical and serum parameters on severe urinary sepsis after renal obstruction.] / Importancia de los parámetros clínicos y analíticos de la sepsis grave en la uropatía obstructiva.

INTRODUCTION: Urosepsis is an underdiagnosed entity with high morbidity and mortality and significant associated costs. The delay in diagnosis leads to an increased risk of multiorgan failure and death. Although its prognosis is better than that of other sepsis, the mortality rate is 20 - 40%. OBJECTIVE: Describe the obstructive uropathy cases (OU) that are complicated by severe sepsis (SS) and identify early biomarkers of SS. MATERIAL AND METHODS: Observational and prospective study of 65 patients with urgent high OU. All patients were evaluated at three different times (0, 24 and 48 hours). An SS predictor model has been constructed and a multivariate risk analysis has been carried out. RESULTS: 64.61% (n=42) developed SS (NSS: n=13). The only statistically significant variables in the 3 moments evaluated and that obtained a good area under the curve [AUROC (>0.70)] were the elevation of neutrophils, procalcitonin, and decrease of bicarbonate. At the time of patient admission, the variable that best predicted SS was the elevation of procalcitonin (AUROC:0.919). SS risk factors (p<0.005) were the history of cancer immunosuppression, and/or urinary tract surgeries, complete UO and high blood values of lactate, potassium and decrease of bicarbonate. The potassium-lactate combination on admission predicted SS with a probability function of 0.805. CONCLUSIONS: There is an analytical profile maintained over the time characteristic of SS that allows anearly identification of patients with OU subsidiary of been complicated with SS.

INTRODUCCIÓN: La Sepsis urinaria obstructiva (SUO) es una entidad infradiagnosticada con una elevada morbimortalidad e importantes costes asociados. El retraso en su diagnóstico condiciona un mayor riesgo de fracaso multiorgánico y fallecimiento. Aunque su pronóstico es mejor que el de otros focos de sepsis, su mortalidad es del 20 - 40%. OBJETIVO: Describir los cuadros de uropatía obstructiva (UO) que se complican con sepsis grave (SG) e identificarlos biomarcadores diagnósticos de SG en la UOde forma precoz.MATERIAL Y MÉTODOS: Estudio observacional y prospectivo de 72 pacientes con UO alta ingresados de manera urgente en el Servicio de Urología del Hospital Clínico Universitario de Valladolid. Todos los pacientes del estudio fueron evaluados en tres momentos diferentes (0, 24 y 48 horas). Se ha creado un modelo predictor de SG y se ha realizado un análisis multivariante de riesgo. RESULTADOS: El 64,61% de los pacientes (n=42) desarrolló SG (NSG: n=13). Las únicas variables estadísticamente significativas en los tres momentos evaluados y que obtenían una buena área bajo la curva [AUROC (>0,70)] fueron la elevación de neutrófilos y procalcitonina y la disminución de bicarbonato. En el momento del ingreso la variable que mejor predecía SG fue la elevación de procalcitonina (AUROC: 0,919). Los factores de riesgo de SG (p<0,05) fueron los antecedentes de cáncer, la inmunosupresión y/o cirugías de vías urinarias, la UO completa y los valores elevados en sangre de lactato y potasio y la disminución del bicarbonato en la gasometría venosa. La combinación potasio-lactato al ingreso predecía SG con una función de probabilidad de 0,805. CONCLUSIONES: Existe un perfil analítico, mantenido en el tiempo, característico de SG que permite la identificación precoz de los pacientes con UO subsidiarios de complicarse con SG.

Importancia de los parámetros clínicos y analíticos de la sepsis grave en la uropatía obstructiva / Relevance of clinical and serum parameters on severe urinary sepsis after renal obstruction

INTRODUCCIÓN: La Sepsis urinaria obstructiva (SUO) es una entidad infradiagnosticada con una elevada morbimortalidad e importantes costes asociados. El retraso en su diagnóstico condiciona un mayor riesgo de fracaso multiorgánico y fallecimiento. Aunque su pronóstico es mejor que el de otros focos de sepsis, su mortalidad es del 20 - 40%. OBJETIVO: Describir los cuadros de uropatía obstructiva (UO) que se complican con sepsis grave (SG) e identificarlos biomarcadores diagnósticos de SG en la UOde forma precoz. MATERIAL Y MÉTODOS: Estudio observacional y prospectivo de 72 pacientes con UO alta ingresados de manera urgente en el Servicio de Urología del Hospital Clínico Universitario de Valladolid. Todos los pacientes del estudio fueron evaluados en tres momentos diferentes (0, 24 y 48 horas). Se ha creado un modelo predictor de SG y se ha realizado un análisis multivariante de riesgo. RESULTADOS: El 64,61% de los pacientes (n=42) desarrolló SG (NSG: n=13). Las únicas variables estadísticamente significativas en los tres momentos evaluados y que obtenían una buena área bajo la curva [AUROC (>0,70)] fueron la elevación de neutrófilos y procalcitonina y la disminución de bicarbonato. En el momento del ingreso la variable que mejor predecía SG fue la elevación de procalcitonina (AUROC: 0,919). Los factores de riesgo de SG (p < 0,05) fueron los antecedentes de cáncer, la inmunosupresión y/o cirugías de vías urinarias, la UO completa y los valores elevados en sangre de lactato y potasio y la disminución del bicarbonato en la gasometría venosa. La combinación potasio-lactato al ingreso predecía SG con una función de probabilidad de 0,805. CONCLUSIONES: Existe un perfil analítico, mantenido en el tiempo, característico de SG que permite la identificación precoz de los pacientes con UO subsidiarios de complicarse con SG

INTRODUCTION: Urosepsis is an underdiagnosed entity with high morbidity and mortality and significant associated costs. The delay in diagnosis leads to an increased risk of multiorgan failure and death. Although its prognosis is better than that of other sepsis, the mortality rate is 20 - 40%. OBJECTIVE: Describe the obstructive uropathy cases (OU) that are complicated by severe sepsis (SS) and identify early biomarkers of SS. MATERIAL AND METHODS: Observational and prospective study of 65 patients with urgent high OU. All patients were evaluated at three different times (0, 24 and 48 hours). An SS predictor model has been constructed and a multivariate risk analysis has been carried out. RESULTS: 64.61% (n=42) developed SS (NSS: n=13). The only statistically significant variables in the 3 moments evaluated and that obtained a good area under the curve [AUROC (>0.70)] were the elevation of neutrophils, procalcitonin, and decrease of bicarbonate. At the time of patient admission, the variable that best predicted SS was the elevation of procalcitonin (AUROC: 0.919). SS risk factors (p < 0.05) were the history of cancer, immunosuppression, and/or urinary tract surgeries, complete UO and high blood values of lactate, potassium and decrease of bicarbonate. The potassium-lactate combination on admission predicted SS with a probability function of 0.805. CONCLUSIONS: There is an analytical profile maintained over the time characteristic of SS that allows an early identification of patients with OU subsidiary of been complicated with SS

Factores pronósticos en cáncer renal con trombo en vena. Análisis de supervivencia / Prognostic factors in renal cancer with venous thrombus survival analysis

OBJETIVO: Analizar el tratamiento quirúrgico en el cáncer renal con trombo venoso a distintos niveles, así como las complicaciones perioperatorias y los diversos factores pronósticos relacionados a supervivencia global, cáncer específica y libre de enfermedad. MÉTODOS: Estudio descriptivo retrospectivo de 42 casos de cáncer renal con trombo venoso entre 2005 y 2015. El nivel alcanzado por el trombo se estableció según la clasificación de la Clínica Mayo. Las complicaciones postoperatorias se estadificaron según la clasificación de Clavien-Dindo. RESULTADOS: Predominio masculino con media de edad de 65,7 años. El 16,6% correspondieron a tumores con trombo de nivel II. En el 58,9% se realizó un abordaje subcostal. En 2 pacientes se estableció hipotermia con parada cardíaca y circulación extracorpórea. En 3 pacientes se realizó resección de lesiones metastásicas durante la nefrectomía radical. La necesidad de reintervención fue del 2,3% mientras que, la mortalidad perioperatoria fue del 4,7%. El 30% debutaron con metástasis al diagnóstico. Veinte pacientes progresaron a 15,5 meses (3-55). La supervivencia global fue de 60 meses. La mortalidad cáncer específica fue del 75%. La supervivencia libre de enfermedad fue del 30% a 55 meses. CONCLUSIONES: El tratamiento quirúrgico del cáncer renal con trombo venoso precisa un manejo multidisciplinar. La técnica quirúrgica seleccionada varía en función del nivel del trombo tumoral. El estadiaje tumoral es el factor pronóstico de mayor importancia. El nivel del trombo influye en el pronóstico, teniendo una supervivencia mayor aquellos pacientes con trombo confinado en vena renal (pT3a) frente a los tumores con trombo en aurícula (pT3c)

OBJECTIVES: To analyze surgery for renal cancer with venous thrombus at different levels, perioperative complications and prognostic factors associated to overall, cancer-specific and disease-free survival. MATERIAL AND METHODS: Retrospective analysis of 42 cases of renal cancer with venous thrombus performed between 2005 and 2015. The level reached by the thrombus was established according to the Mayo Clinic classification. Postoperative complications were staged according to Clavien-Dindo classification. RESULTS: Most frequent in males. Mean age 65.7 years. 16.6% were tumors with level II thrombus. Subcostal approach was performed in 58.9%. Extracorporeal circulation with cardiac arrest and hypothermia was established in 2 patients. Resection of metastatic disease was performed in 3 patients during radical nephrectomy. Reoperation was 2.3% while, perioperative mortality was 4.7%. 30% presented with metastases at diagnosis. Twenty patients progressed at 15.5 months (3-55). Overall survival was 60 months. The cancer-specific mortality was 75%. Disease-free survival was 30% at 55 months.CONCLUSIONS: Surgical treatment of renal cancer with venous thrombus requires a multidisciplinary management. The surgical technique varies according to the level reached by the venous thrombus. Tumor stage is the most important prognostic factor. Thrombus level influences prognosis, with longer survival for patients with tumor thrombus confined to the renal vein (pT3a) in comparison to tumors with thrombus in the atrium (pT3c)

[Prognostic factors in renal cancer with venous thrombus survival analysis.] / Factores pronósticos en cáncer renal con trombo en vena. Análisis de supervivencia.

OBJECTIVES: To analyze surgery for renal cancer with venous thrombus at different levels, perioperative complications and prognostic factors associated to overall, cancer-specific and disease-free survival. MATERIAL AND METHODS: Retrospective analysis of 42 cases of renal cancer with venous thrombus performed between 2005 and 2015. The level reached by the thrombus was established according to the Mayo Clinic classification. Postoperative complications were staged according to Clavien-Dindo classification. RESULTS: Most frequent in males. Mean age 65.7 years. 16.6% were tumors with level II thrombus. Subcostal approach was performed in 58.9%. Extracorporeal circulation with cardiac arrest and hypothermia was established in 2 patients. Resection of metastatic disease was performed in 3 patients during radical nephrectomy. Reoperation was 2.3% while, perioperative mortality was 4.7%. 30% presented with metastases at diagnosis. Twenty patients progressed at 15.5 months (3-55). Overall survival was 60 months. The cancer-specific mortality was 75%. Disease-free survival was 30% at 55 months. CONCLUSIONS: Surgical treatment of renal cancer with venous thrombus requires a multidisciplinary management. The surgical technique varies according to the level reached by the venous thrombus. Tumor stage is the most important prognostic factor. Thrombus level influences prognosis, with longer survival for patients with tumor thrombus confined to the renal vein (pT3a) in comparison to tumors with thrombus in the atrium (pT3c).

[Small cell carcinoma of the bladder: Our experience]. / CARCINOMA DE CÉLULAS PEQUEÑAS DE VEJIGA.

OBJECTIVES: Small cell carcinoma of the bladder shows low incidence and poor survival; thus, treatment algorithms based on randomized studies are unavailable. The aim of the present study is to review our case series. METHODS: Observational retrospective study of 10 patients diagnosed with small cell carcinoma of the bladder between 2006 and 2013. RESULTS: Mean age was 65.7 years; There was only one female in the cohort. In all cases hematuria was the fist symptom. 4 cases presented high-grade papillary urothelial carcinoma with small cell carcinoma. Radical cystectomy was performed in 40% patients, in combination with chemotherapy, radiotherapy or both. Median survival was 330 days (IC 95%: 40.757- 619.243) and only one patient showed complete response. CONCLUSIONS: Even when small cell carcinoma of the bladder is a low incidence tumor, its prognosis is worse than that of urothelial carcinoma. Although further randomized studies are needed to best define treatment, this study shows that survival at local stages is optimized by neoadjuvant chemotherapy, followed by radical resection, as the literature suggests.

Carcinoma de células pequeñas de vejiga / Small cell carcinoma of the bladder: Our experience

OBJETIVO: El carcinoma vesical de células pequeñas presenta una baja incidencia y escasa supervivencia, por lo que no existen esquemas terapéuticos basados en estudios randomizados. Nos planteamos como objetivo revisar nuestra casuística. MÉTODOS: Estudio observacional retrospectivo de 10 pacientes diagnosticados de carcinoma de células pequeñas entre 2006 y 2013. RESULTADOS: La edad media fue de 65,7 años y sólo se presentó en una mujer de los 10 pacientes. Se relacionó en su totalidad con antecedentes de tabaquismo, siendo la forma de presentación la hematuria. 4 casos presentaban carcinoma urotelial de alto grado junto con el componente microcítico. Se realizó cistectomía radical en el 40% de los pacientes, recibiendo además tratamiento con quimioterapia, radioterapia o ambos. La mediana del tiempo de supervivencia fue de 330 días (IC 95%: 40,757 - 619,243). Sólo en un caso obtuvimos respuesta completa. CONCLUSIONES: El carcinoma de células pequeñas de vejiga es un tumor con baja incidencia pero de peor pronóstico que los tumores uroteliales. Aunque se necesiten más estudios randomizados para definir el mejor tratamiento, y nuestra casuística sea limitada, se ha publicado que los mejores resultados en cuanto a supervivencia en los estadios localizados se consiguen con quimioterapia neoayuvante seguida de cirugía radical

OBJECTIVES: Small cell carcinoma of the bladder shows low incidence and poor survival; thus, treatment algorithms based on randomized studies are unavailable. The aim of the present study is to review our case series. METHODS: Observational retrospective study of 10 patients diagnosed with small cell carcinoma of the bladder between 2006 and 2013. RESULTS: Mean age was 65.7 years; There was only one female in the cohort. In all cases hematuria was the fist symptom. 4 cases presented high-grade papillary urothelial carcinoma with small cell carcinoma. Radical cystectomy was performed in 40% patients, in combination with chemotherapy, radiotherapy or both. Median survival was 330 days (IC 95%: 40.757- 619.243) and only one patient showed complete response. CONCLUSIONS: Even when small cell carcinoma of the bladder is a low incidence tumor, its prognosis is worse than that of urothelial carcinoma. Although further randomized studies are needed to best define treatment, this study shows that survival at local stages is optimized by neoadjuvant chemotherapy, followed by radical resection, as the literature suggests

Indicaciones y complicaciones de la embolización renal: análisis retrospectivo / Indications and complications of renal embolization: a retrospective analysis

La embolización renal es un procedimiento intervencionista, cuyas aplicaciones terapéuticas han variado a lo largo del tiempo. Realizamos una revisión retrospectiva de 48 embolizaciones, analizando las causas y complicaciones asociadas a esta técnica. Nuestra indicación principal fue la embolización prequirúrgica de tumores renales de gran tamaño, aunque la indicación de mayor relevancia clínica actual es el tratamiento conservador de fístulas arterio-venosas iatrogénicas, angiomiolipomas o traumatismos renales con sangrado activo. La complicación menor más frecuente es el síndrome post-embolización (52.8 por ciento), situación que remite fácilmente con tratamiento médico. Como complicaciones mayores destacan la sepsis y la migración de material embolígeno, ambos muy poco frecuentes en nuestra serie...

Renal embolization is an interventional procedure, whose therapeutic applications have varied over time. We conducted a retrospective review of 48 embolizations, analyzing the causes and complications associated with this technique. Our main indication was the preoperative embolization of large renal tumors, although the most relevant indication today is the conservative treatment of iatrogenic arteriovenous fistula, angiomyolipomas or renal trauma with active bleeding. The most common minor complication is post-embolization syndrome (52.8 percent), a situation that is easily managed with medical treatment. Major complications include sepsis and migration of embolic material and both are very rare in our series...

[Tumors of the upper urinary tract. Our experience]. / Tumores del tracto urinario superior. Nuestra experiencia.

OBJECTIVES: To study the clinical presentation, diagnosis, treatment, and evolution of upper urinary tract tumours. METHODS: We carried out a retrospective study on the upper urinary tract tumours treated in our centre, HCU Valladolid, between 1994 and 2007. RESULTS: 65 tumours were diagnosed, although only 59 were valid for the study. Mean patient age was 68 years (interval between 46 and 88 years). 47 were men and 12 women. The most common symptom on presentation was hematuria (79.9%). Urography was the most frequently used diagnostic technique (96.6%) and nephroureterectomy with transurethral resection of the intramural ureter was the most common surgical treatment performed, carried out in 28 cases. 9 patients underwent percutaneous treatment with only one recurrence, and 2 patients received ureteroscopic treatment. 50.9% of the lesions were classified as superficial tumours. The 5 and 10-year survival rates were 55 and 47%. CONCLUSIONS: Upper urinary tract tumours are an unusual disease characteristic of medium-advanced ages. Nowadays nephroureterectomy by open surgery or laparoscopy is the standard treatment. Conservative endoscopic procedures have more and more importance and present excellent results in highly selected cases.

[Pelvic recurrence after radical cystectomy for bladder cancer]. / Recidiva pelviana despues de cistectomia radical por cancer vesical.

OBJECTIVES: We report the case of a male patient who had undergone radical cystectomy and orthotopic neobladder for bladder cancer presenting with local recurrence eight months later. METHODS: Diagnostic tests included CT scan and ultrasound guided transrectal biopsy RESULTS: With the diagnosis of local recurrence he underwent chemotherapy and radiotherapy CONCLUSIONS: The pelvic recurrence of transitional cell carcinoma after radical cystectomy is rare and prognosis is poor. It is frequently associated with advanced tumor stage. It should be treated by a multidisciplinary approach.

Recidiva pelviana después de cistectomía radical por cáncer vesical / Pelvic recurrence after radical cystectomy for bladder cancer

OBJETIVO: Presentamos un caso de unvarón sometido a cistectomía radical con neovejiga ortotópicapor cáncer vesical, con recurrencia local desarrolladoa los 8 meses.MÉTODO: Los estudios diagnósticos incluyen TAC y biopsiatransrectal ecodirigida.RESULTADO: Con el diagnóstico de recurrencia local, fuetratado con quimioterapia y radioterapia.CONCLUSIONES: La recurrencia pélvica por carcinomatransicional después de cistectomía radical, es infrecuentey con pobre pronóstico. Está frecuentemente asociado conestadio tumoral avanzado. Debe ser tratado con abordajemultidisciplinario

OBJECTIVES: We report the case of a male ;;patient who had undergone radical cystectomy and ;;orthotopic neobladder for bladder cancer presenting with ;;local recurrence eight months later. ;;METHODS: Diagnostic tests included CT scan and ;;ultrasound guided transrectal biopsy. ;;RESULTS: With the diagnosis of local recurrence he ;;underwent chemotherapy and radiotherapy. ;;CONCLUSIONS: The pelvic recurrence of transitional cell ;;carcinoma after radical cystectomy is rare and prognosis is ;;poor. It is frequently associated with advanced tumor ;;stage. It should be treated by a multidisciplinary approach